Compliance With LDL-Lowering Therapy (Study P05467)(COMPLETED)

Last updated: February 7, 2022
Sponsor: Organon and Co
Overall Status: Completed

Phase

N/A

Condition

Coronary Artery Disease

Heart Disease

Thrombosis

Treatment

N/A

Clinical Study ID

NCT00723723
P05467
  • Ages > 18
  • All Genders

Study Summary

This observational study is being conducted in patients receiving statin treatment as secondary prevention of coronary heart disease under the current standard of care in compliance with European guidelines. The purpose of the study is to evaluate the percentage of these patients that reach target LDL levels. Additionally this study will measure the patient's compliance to treatment as assessed by counting the returned tablets. Both assessments will be made at visits conducted 6-8 weeks after the first visit and 28-32 weeks after the first visit.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • willingness to participate in the study
  • 18 years of age or more
  • clinically established cardiovascular disease to be considered as patients insecondary prevention
  • prior therapy with any statin without achieving goal (2.5 mmol/L of LDL cholesterol)at last lipid check performed

Exclusion

Exclusion Criteria:

  • None

Study Design

Total Participants: 555
Study Start date:
January 01, 2008
Estimated Completion Date:
June 30, 2009